STUDY OF USE OF CEFDINIR VERSUS CEPHALEXIN FOR TREATMENT OF SKIN INFECTIONS IN PEDIATRIC-PATIENTS

Three hundred ninety-four patients, aged 6 months to 12 years, entered a multicenter, randomized, controlled, investigator-blind study compa ring cefdinir, 7 mg/kg of body weight twice a day,,vith cephalexin, 10 mg/kg four times a day, each given for 10 days. The most common infec tions treated were impetigo and secondary infection of preexisting der matitis. The most common pathogens isolated were Staphylococcus aureus and Streptococcus pyogenes. Two hundred thirty-one patients were micr obiologically evaluable, Microbiologic eradication rates were 164 of 1 65 pathogens (99.4%) in the cefdinir group and 152 of 156 pathogens (9 7.3%) in the cephalexin group (P = 0.14), Clinical cure rates were 116 of 118 patients (98.3%) in the cefdinir group and 106 of 113 patients (93.8%) in the cephalexin group (P = 0.056), Sixteen percent of cefdi nir patients and 11% of cephalexin patients experienced adverse events (P = 0.11), the most common being diarrhea, which affected 8% of the cefdinir group and 4% of the cephalexin group, Cefdinir appears to be an effective and well-tolerated agent for the treatment of uncomplicat ed skin and skin structure infections in pediatric patients.